Uricase and Other Novel Agents for the Management of Patients with Treatment-failure Gout

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2007 May 29

PMID 17531181

Citations 12

Authors

John S Sundy

Michael S Hershfield

Affiliations

Soon will be listed here.

Abstract

Successful management of chronic gout depends on reducing body pools of urate. The benchmark of success is to maintain serum urate levels at less than 6 mg/dL using therapies such as probenecid or allopurinol. In a subset of patients with gout, these medications fail to achieve this benchmark, resulting in ongoing signs and symptoms characteristic of treatment-failure gout. Potential therapies now in clinical development show promise for treating this refractory patient population. In this article, we review the clinical characteristics associated with treatment-failure gout and discuss recent data from clinical trials of febuxostat and uricase.

Citing Articles

ASC-1 Isolated from Pickled Cabbage Ameliorates Hyperuricemia by Degrading Uric Acid in Rats.

Zhu W, Bi S, Fang Z, Iddrisu L, Deng Q, Sun L Microorganisms. 2024; 12(4).

PMID: 38674776 PMC: 11052324. DOI: 10.3390/microorganisms12040832.

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110).

Kivitz A, DeHaan W, Azeem R, Park J, Rhodes S, Inshaw J Rheumatol Ther. 2023; 10(4):825-847.

PMID: 37069364 PMC: 10326180. DOI: 10.1007/s40744-023-00546-0.

Probiotic GR-3 ameliorates human hyperuricemia via degrading and promoting excretion of uric acid.

Zhao S, Feng P, Hu X, Cao W, Liu P, Han H iScience. 2022; 25(10):105198.

PMID: 36248735 PMC: 9556918. DOI: 10.1016/j.isci.2022.105198.

Epidermal growth factor gene is a newly identified candidate gene for gout.

Han L, Cao C, Jia Z, Liu S, Liu Z, Xin R Sci Rep. 2016; 6:31082.

PMID: 27506295 PMC: 4978989. DOI: 10.1038/srep31082.

Correlation of GLUT9 Polymorphisms With Gout Risk.

Meng Q, Yue J, Shang M, Shan Q, Qi J, Mao Z Medicine (Baltimore). 2015; 94(44):e1742.

PMID: 26554771 PMC: 4915872. DOI: 10.1097/MD.0000000000001742.

References

Pal B, Foxall M, Dysart T, Carey F, Whittaker M . How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol. 2000; 19(1):21-5. DOI: 10.1007/s100670050005. View

Becker M, Schumacher Jr H, Wortmann R, MacDonald P, Eustace D, Palo W . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-61. DOI: 10.1056/NEJMoa050373. View

Perez-Ruiz F, Calabozo M, Pijoan J, Herrero-Beites A, Ruibal A . Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47(4):356-60. DOI: 10.1002/art.10511. View

Hande K, Noone R, Stone W . Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984; 76(1):47-56. DOI: 10.1016/0002-9343(84)90743-5. View

Riedel A, Nelson M, Joseph-Ridge N, Wallace K, Macdonald P, Becker M . Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004; 31(8):1575-81. View

Becker M, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B . Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004; 23(8-9):1111-6. DOI: 10.1081/NCN-200027372. View

de Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S . Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003; 30(1):44-54. View

Smith P, Karlson N, Nair B . Quality use of allopurinol in the elderly. J Qual Clin Pract. 2000; 20(1):42-3. DOI: 10.1046/j.1440-1762.2000.00353.x. View

Sundy J, Ganson N, Kelly S, Scarlett E, Rehrig C, Huang W . Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007; 56(3):1021-8. DOI: 10.1002/art.22403. View

10.

Sarawate C, Patel P, Schumacher H, Yang W, Brewer K, Bakst A . Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006; 12(2):61-5. DOI: 10.1097/01.rhu.0000209882.50228.9f. View

11.

Moolenburgh J, Reinders M, Jansen T . Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol. 2005; 25(5):749-52. DOI: 10.1007/s10067-005-0043-y. View

12.

Chua C, Greenberg M, Viau A, Nucci M, Brenckman Jr W, Hershfield M . Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med. 1988; 109(2):114-7. DOI: 10.7326/0003-4819-109-2-114. View

13.

Dalbeth N, Kumar S, Stamp L, Gow P . Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006; 33(8):1646-50. View

14.

Sundy J, Becker M, Baraf H, Barkhuizen A, Moreland L, Huang W . Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008; 58(9):2882-91. DOI: 10.1002/art.23810. View

15.

Mikuls T, Maclean C, Olivieri J, Patino F, Allison J, Farrar J . Quality of care indicators for gout management. Arthritis Rheum. 2004; 50(3):937-43. DOI: 10.1002/art.20102. View

16.

Rozenberg S, Roche B, Dorent R, Koeger A, Borget C, Wrona N . Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed. 1995; 62(5):392-4. View

17.

Ganson N, Kelly S, Scarlett E, Sundy J, Hershfield M . Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2005; 8(1):R12. PMC: 1526556. DOI: 10.1186/ar1861. View

18.

Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K . PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 2004; 23(8-9):1117-8. DOI: 10.1081/NCN-200027377. View

19.

Fang W, Zeng X, Li M, Chen L, Schumacher Jr H, Zhang F . The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol. 2006; 33(10):2041-9. View

20.

Richette P, Bardin T . Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol. 2006; 2(6):338-42. DOI: 10.1038/ncprheum0214. View